Eli Lilly’s Foundayo Joins TrumpRx Platform Following Expedited FDA Approval
The Food and Drug Administration approved Eli Lilly’s once daily weight loss pill, Foundayo, on April 1, 2026. This decision occurred just 50 days after the initial filing. The agency cleared the medication for adults with obesity or weight related comorbidities. Patients must use the drug alongside physical activity and a reduced calorie diet.
Foundayo represents the second oral GLP-1 receptor agonist to receive federal clearance. This follows the December 2025 approval of an oral version of semaglutide. Shipping will begin through direct to consumer platforms on April 6. Retail pharmacies will stock the medication shortly thereafter.
The agency utilized the Commissioner’s National Priority Voucher program for this review. This pilot initiative reduces standard 10 month timelines to approximately 60 days. Critics within the agency expressed concerns regarding possible political influence. Federal officials maintained that scientific standards remained intact throughout the process.
The manufacturer received the priority voucher through an agreement with the White House. This deal aims to lower drug prices within specific clinical settings. Continuous communication between the agency and the company facilitated the rapid timeline. Regulatory leaders emphasized that this speed did not compromise safety evaluations.
Foundayo operates as a small molecule GLP-1 receptor agonist with unique dosing flexibility. Patients may take the pill at any time without food or water restrictions. This provides a significant advantage over existing oral alternatives requiring an empty stomach. In light of this, the drug offers improved patient convenience.
Phase 3 clinical trials demonstrated an average weight loss of 12.4 percent over 72 weeks. These results align with other oral agents but trail the efficacy of injectable options. Moreover, the medication improved cardiovascular markers and reduced systolic blood pressure. Significant reductions in waist circumference and cholesterol levels occurred across all doses.
The TrumpRx cost comparison platform now features Foundayo for uninsured individuals. Initial doses will cost 149 dollars through the use of available coupons. Subsequent refills will range between 199 and 299 dollars. Consequently, the platform provides a centralized resource for evaluating weight loss options.
Seniors enrolled in Medicare Part D will gain access this summer. These patients will pay approximately 50 dollars per month for the treatment. Along with this, commercially insured individuals may pay as little as 25 dollars. This pricing structure results from a three way agreement involving the federal government.
The medication mimics natural hormones that regulate appetite and satiety. This biological mechanism matches the function of widely used injectable therapies. Nevertheless, patients often report nausea and constipation during the initial treatment phases. These gastrointestinal reactions align with the broader GLP-1 drug class.
The drug carries a mandatory warning regarding potential thyroid tumor risks. Patients with a family history of medullary thyroid carcinoma must avoid this treatment. Furthermore, the medication may reduce the efficacy of oral contraceptives. Prescribers should evaluate these risks before initiating a patient’s regimen.
Analysts project annual sales for Foundayo will reach 14.79 billion dollars by 2030. This figure remains lower than projections for the company’s injectable agents. Many insurers have not yet committed to broad coverage for the new pill. Therefore, out of pocket costs remain a barrier for many households.
The White House continues to promote the national cost comparison platform. Officials believe this tool offers more comprehensive data than individual manufacturer websites. Building on this, the administration aims to lower the entry price for obesity therapies. Market analysts will monitor insurance adoption rates throughout the coming year.
